Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Fludarabine is one of the most recent and promising therapeutic agents for chronic lymphocytic leukaemia. We describe a patient who developed tumour lysis syndrome after the first course of treatment with fludarabine and call attention to this uncommon but potentially lethal complication that has not been previously taken into account in this neoplasia. It should always be anticipated when patients are treated with new and effective drugs.
Department of Internal Medicine, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
C
C
Montalban
F
F
Liaño
A
A
Aguilera
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D015275:Tumor Lysis Syndrome / Q000209:etiology*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine